{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:40:03Z","timestamp":1786995603507,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","award":["2646173"],"award-info":[{"award-number":["2646173"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","award":["17K10286"],"award-info":[{"award-number":["17K10286"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Intramural Research Grant"},{"DOI":"10.13039\/501100001695","name":"JST","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001695","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pharmthera.2019.107427","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T11:58:05Z","timestamp":1571745485000},"page":"107427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Research and development of \u03ba opioid receptor agonists and \u03b4 opioid receptor agonists"],"prefix":"10.1016","volume":"205","author":[{"given":"Hiroshi","family":"Nagase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107427_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.118.249839","article-title":"In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder","volume":"367","author":"Bidlack","year":"2018","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)38837-8","article-title":"Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity","volume":"296","author":"Brandt","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0893-133X(01)00413-4","article-title":"Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats","volume":"26","author":"Broom","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.04.009","article-title":"Targeting opioid dysregulation in depression for the development of novel therapeutics","author":"Browne","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/128_2010_83","article-title":"Nonpeptidic delta (delta) opioid agonists and antagonists of the diarylmethylpiperazine class: what have we learned?","volume":"299","author":"Calderon","year":"2011","journal-title":"Topics in Current Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bph.13374","article-title":"\u03b2-Arrestin 2 dependence of \u03b4 opioid receptor agonists is correlated with alcohol intake","volume":"173","author":"Chiang","year":"2016","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbr.2014.10.029","article-title":"Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures","volume":"278","author":"Chung","year":"2015","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/toxsci\/kfq200","article-title":"Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine","volume":"117","author":"Codd","year":"2010","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0045","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-3565(25)39544-3","article-title":"Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice","volume":"267","author":"Comer","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0050","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neubiorev.2005.03.008","article-title":"Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test","volume":"29","author":"Cryan","year":"2005","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0014-827X(99)00005-1","article-title":"Serum beta-endorphin level in patients with depression on fluvoxamine","volume":"54","author":"Djurovi\u0107","year":"1999","journal-title":"Farmaco"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejphar.2008.12.021","article-title":"The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats","volume":"604","author":"Do Carmo","year":"2009","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/76061","article-title":"Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses","volume":"25","author":"Filliol","year":"2000","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0075","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.bjp.0703248","article-title":"Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation","volume":"129","author":"Fraser","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/13543776.2013.804066","article-title":"Non-peptidic \u03b4 opioid receptor agonists and antagonists (2000-2012)","volume":"23","author":"Fujii","year":"2013","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1742-7843.2005.pto_97107.x","article-title":"A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80","volume":"97","author":"Gallantine","year":"2005","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0090","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/ja01588a033","article-title":"The synthesis of morphine","volume":"78","author":"Gates","year":"1956","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/FBP.0b013e32834a1f2c","article-title":"Delta opioid receptor analgesia: Recent contributions from pharmacology and molecular approaches","volume":"22","author":"Gav\u00e9riaux-Ruff","year":"2011","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0100","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.pain.2010.12.031","article-title":"Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia","volume":"152","author":"Gaveriaux-Ruff","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbr.2016.11.008","article-title":"Effects of repeated treatment with a delta opioid receptor agonist KNT-127 on hyperemotionality in olfactory-bulbectomized rats","volume":"323","author":"Gotoh","year":"2017","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnmol.2018.00100","article-title":"Delta opioid receptor signaling promotes resilience to stress under the repeated social defeat paradigm in mice","volume":"11","author":"Henry","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbr.2016.06.045","article-title":"Involvement of glutamatergic N-methyl-d-aspartate receptors in the expression of increased head-dipping behaviors in the hole-board tests of olfactory bulbectomized mice","volume":"312","author":"Hirose","year":"2016","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1124\/jpet.111.179432","article-title":"Preclinical pharmacology of AZD2327: a highly selective agonist of the \u03b4-opioid receptor","volume":"338","author":"Hudzik","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1749-6632.1982.tb39512.x","article-title":"beta-Endorphin immunoreactivity in the plasma of psychiatric patients receiving electroconvulsive treatment","volume":"398","author":"Inturrisi","year":"1982","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00008877-200311000-00003","article-title":"Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats","volume":"14","author":"Jutkiewicz","year":"2003","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.103.061242","article-title":"Delta-opioid agonists: Differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats","volume":"309","author":"Jutkiewicz","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0893-133X(99)00090-1","article-title":"Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines","volume":"22","author":"Kang","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0145","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1016\/j.bmc.2008.09.011","article-title":"Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists","volume":"16","author":"Kawai","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0163-7258(97)00004-1","article-title":"The olfactory bulbectomized rat as a model of depression: an update","volume":"74","author":"Kelly","year":"1997","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0155","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-3565(25)21059-X","article-title":"Sympathoadrenal, cardiovascular and blood gas responses to highly selective mu and delta opioid peptides","volume":"251","author":"Kiritsy-Roy","year":"1989","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0922-4106(95)90134-5","article-title":"Properties of TAN-67, a nonpeptidic delta-opioid receptor agonist, at cloned human delta- and mu-opioid receptors","volume":"291","author":"Knapp","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0165","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1176\/ajp.150.11.1761","article-title":"beta-Endorphin and specific clinical symptoms of depression","volume":"150","author":"Kravitz","year":"1993","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0170","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/0024-3205(82)90132-1","article-title":"Properties of a selective kappa agonist, U-50,488H","volume":"31","author":"Lahti","year":"1982","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0175","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1021\/jm900773n","article-title":"Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4\u2032-piperidine]-4-yl) benzamide (ADL5747)","volume":"52","author":"Le Bourdonnec","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: Distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0185","first-page":"2445","article-title":"Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain","volume":"7","author":"Mansour","year":"1987","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0166-2236(95)93946-U","article-title":"Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications","volume":"18","author":"Mansour","year":"1995","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0195","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0200","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.celrep.2013.10.015","article-title":"Select G-protein-coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and \u03b2-arrestin 1 pathway","volume":"5","author":"Mittal","year":"2013","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0205","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1021\/jo00278a025","article-title":"The facility of formation of a \u25b3 6 bond in Dihydromorphinone and related opiates","volume":"54","author":"Nagase","year":"1989","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0210","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1248\/cpb.46.1695","article-title":"Rational drug design and synthesis of a highly selective nonpeptide delta-opioid agonist, (4aS*,12aR*)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octahydropyrido[3,4-b]acridine (TAN-67)","volume":"46","author":"Nagase","year":"1998","journal-title":"Chemical and Pharmaceutical Bulletin (Tokyo)"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0215","unstructured":"Nagase, H., Wakita, H., Kawai, K., Endo, T., & Matsumoto, O. (1992). Toray, Isoquinoline derivatives and uses thereof. JP04275288."},{"key":"10.1016\/j.pharmthera.2019.107427_bib0220","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0024-3205(01)01010-4","article-title":"The pharmacological profile of delta opioid receptor ligands, (+) and (-) TAN-67 on pain modulation","volume":"68","author":"Nagase","year":"2001","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0225","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.bmcl.2009.03.099","article-title":"Design and synthesis of novel delta opioid receptor agonists and their pharmacologies","volume":"19","author":"Nagase","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0230","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1016\/j.bmcl.2010.08.083","article-title":"Design and synthesis of KNT-127, a delta-opioid receptor agonist effective by systemic administration","volume":"20","author":"Nagase","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-6606-4-25","article-title":"Regulation of opioid receptor signalling: implications for the development of analgesic tolerance","volume":"4","author":"Nagi","year":"2011","journal-title":"Molecular Brain"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0240","first-page":"63","article-title":"Receptor-mediated beta-arrestin signaling modulates convulsive effects","author":"Nakata","year":"2014","journal-title":"International Narcotic Research Conference 2014"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0022-3565(24)37596-2","article-title":"Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys","volume":"286","author":"Negus","year":"1998","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0250","doi-asserted-by":"crossref","first-page":"7628","DOI":"10.1016\/j.bmc.2013.10.032","article-title":"The most effective influence of 17-(3-ethoxypropyl) substituent on the binding affinity and the agonistic activity in KNT-127 derivatives, \u03b4 opioid receptor agonists","volume":"21","author":"Nemoto","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0255","series-title":"Medicinal chemistry","author":"Nogrady","year":"1985"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0260","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/jpet.111.188987","article-title":"\u03b4-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization","volume":"342","author":"Nozaki","year":"2012","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0265","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1111\/bph.12852","article-title":"In vivo properties of KNT-127, a novel \u03b4 opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice","volume":"171","author":"Nozaki","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0270","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-014-3676-1","article-title":"Riluzole in the prelimbic medial prefrontal cortex attenuates veratrine-induced anxiety-like behaviors in mice","volume":"232","author":"Ohashi","year":"2015","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0275","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjp.0706686","article-title":"Delta opioid receptor ligands modulate anxiety-like behaviors in the rat","volume":"147","author":"Perrine","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0280","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0024-3205(82)90341-1","article-title":"U-50488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse","volume":"31","author":"Piercey","year":"1982","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0285","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: A new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/jm00177a002","article-title":"A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities","volume":"23","author":"Portoghese","year":"1980","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0295","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/jm00385a002","article-title":"Bimorphinans as highly selective, potent kappa opioid receptor antagonists","volume":"30","author":"Portoghese","year":"1987","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/jm00397a001","article-title":"Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists","volume":"31","author":"Portoghese","year":"1988","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","article-title":"The delta opioid receptor: An evolving target for the treatment of brain disorders","volume":"32","author":"Pradhan","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0310","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1073\/pnas.98.4.1958","article-title":"Female preproenkephalin-knockout mice display altered emotional responses","volume":"98","author":"Ragnauth","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0315","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","article-title":"A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression","volume":"233","author":"Richards","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0320","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2016_18","article-title":"Delta Opioid Receptor (DOR) ligands and pharmacology: Development of indolo- and quinolinomorphinan derivatives based on the message-address concept","volume":"247","author":"Saitoh","year":"2018","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0330","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/157015912803217314","article-title":"Antidepressant-like effects of \u03b4 opioid receptor agonists in animal models","volume":"10","author":"Saitoh","year":"2012","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0335","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1254\/jphs.FPJ04014X","article-title":"Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents","volume":"95","author":"Saitoh","year":"2004","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0340","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-005-0112-6","article-title":"Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats","volume":"182","author":"Saitoh","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0345","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00213-007-0699-x","article-title":"Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats","volume":"191","author":"Saitoh","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0350","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brainres.2007.07.095","article-title":"Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model","volume":"1208","author":"Saitoh","year":"2008","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0355","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2011.04.041","article-title":"The novel \u03b4 opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions","volume":"223","author":"Saitoh","year":"2011","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0360","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.neuropharm.2012.11.025","article-title":"The novel \u03b4 opioid receptor agonist KNT-127 produces distinct anxiolytic-like effects in rats without producing the adverse effects associated with benzodiazepines","volume":"67","author":"Saitoh","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0365","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/jnr.23391","article-title":"Activation of the prelimbic medial prefrontal cortex induces anxiety-like behaviors via N-Methyl-D-aspartate receptor-mediated glutamatergic neurotransmission in mice","volume":"92","author":"Saitoh","year":"2014","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0370","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jphs.2018.09.009","article-title":"A delta opioid receptor agonist, KNT-127, in the prelimbic medial prefrontal cortex attenuates glial glutamate transporter blocker-induced anxiety-like behavior in mice","volume":"138","author":"Saitoh","year":"2018","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbr.2017.08.041","article-title":"The delta opioid receptor agonist KNT-127 in the prelimbic medial prefrontal cortex attenuates veratrine-induced anxiety-like behaviors in mice","volume":"336","author":"Saitoh","year":"2018","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0380","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.biopsych.2014.07.033","article-title":"A novel anxiogenic role for the delta opioid receptor expressed in GABAergic forebrain neurons","volume":"77","author":"Chu Sin Chung","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0385","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neubiorev.2005.03.010","article-title":"The olfactory bulbectomised rat as a model of depression","volume":"29","author":"Song","year":"2005","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1124\/jpet.104.082685","volume":"314","author":"Stevenson","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0395","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbr.2016.01.044","article-title":"The infralimbic and prelimbic medial prefrontal cortices have differential functions in the expression of anxiety-like behaviors in mice","volume":"304","author":"Suzuki","year":"2016","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0400","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbr.2010.07.002","article-title":"Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression","volume":"216","author":"Takahashi","year":"2011","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0405","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0014-2999(81)90355-1","article-title":"The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone","volume":"70","author":"Takemori","year":"1981","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0410","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.neuropharm.2012.01.005","article-title":"Novel \u03b41-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex","volume":"62","author":"Tanahashi","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0415","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-3565(25)12605-0","article-title":"Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats","volume":"254","author":"Tavani","year":"1990","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0420","first-page":"22","article-title":"Biased ligands at mu and delta opioid receptors: Targeting selective signalling to develop improved therapeutics","author":"Violin","year":"2014","journal-title":"International Narcotic Research Conference 2014"},{"key":"10.1016\/j.pharmthera.2019.107427_bib0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107792","article-title":"Selective agonists of the \u03b4-opioid receptor, KNT-127 and SNC80, act differentially on extinction learning of contextual fear memory in mice","author":"Yamada","year":"2019","journal-title":"Neuropharmacology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:02:20Z","timestamp":1759010540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":85,"alternative-id":["S0163725819301792"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107427","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research and development of \u03ba opioid receptor agonists and \u03b4 opioid receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107427"}}